We are live on ! Find out more
CMPX icon

Compass Therapeutics
CMPX

73 hedge funds and large institutions have $288M invested in Compass Therapeutics in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $267M → $288M (+$21.1M)

7.11% more ownership

Funds ownership: 64.41% → 71.52% (+7.1%)

1% more funds holding

Funds holding: 72 → 73 (+1)

8% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 24

6% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 18

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
73
Holders Change
+1
Holders Change %
+1.39%
% of All Funds
1.15%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
26
Increased
19
Reduced
18
Closed
24
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$14.1M
2
B
Braidwell
Connecticut
+$8.5M
3
Blackstone Inc
Blackstone Inc
New York
+$4.33M
4
State Street
State Street
Massachusetts
+$4.22M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.9M

Top Sellers

1
FCMV
Foresite Capital Management V
California
-$6.77M
2
Millennium Management
Millennium Management
New York
-$2.56M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.38M
4
FAM
Fred Alger Management
New York
-$1.32M
5
Jane Street
Jane Street
New York
-$1.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$71.1M – – –
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$19.9M – – –
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$19.7M +$673K +214,268 +4%
BlackRock
4
BlackRock
New York
$19.2M +$14.1M +4,491,397 +291%
Blackstone Inc
5
Blackstone Inc
New York
$19.1M +$4.33M +1,379,742 +30%
B
6
Braidwell
Connecticut
$18.9M +$8.5M +2,706,426 +83%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$17.6M -$457K -145,566 -3%
RSCM
8
Rock Springs Capital Management
Maryland
$17.5M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$13M +$1.28M +408,556 +11%
VC
10
Vivo Capital
California
$11.3M – – –
CA
11
CHI Advisors
New York
$9M – – –
MIM
12
Monashee Investment Management
Massachusetts
$6.26M -$652K -207,746 -10%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$5.75M +$2.9M +924,644 +105%
State Street
14
State Street
Massachusetts
$5.55M +$4.22M +1,344,201 +334%
APM
15
Avidity Partners Management
Texas
$5.15M -$643K -204,800 -11%
BBA
16
Baker Bros. Advisors
New York
$4.95M – – –
FCMV
17
Foresite Capital Management V
California
$4.21M -$6.77M -2,156,652 -62%
PM
18
Prosight Management
Texas
$3.45M +$1.27M +405,697 +60%
ABG
19
Ally Bridge Group
New York
$2.91M +$2.87M +914,630 New
Northern Trust
20
Northern Trust
Illinois
$2.45M +$1.84M +584,562 +315%
N
21
Nuveen
North Carolina
$1.25M +$1.23M +391,871 New
Bank of New York Mellon
22
Bank of New York Mellon
New York
$863K +$728K +231,990 +590%
Charles Schwab
23
Charles Schwab
California
$799K +$655K +208,629 +488%
Millennium Management
24
Millennium Management
New York
$520K -$2.56M -814,937 -83%
Swiss National Bank
25
Swiss National Bank
Switzerland
$520K – – –
1
2 3 4

CMPX Hedge Fund Activity: Q2 2023 in Review

73 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q2 2023, worth a combined $288M — up 7.9% from $267M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new CMPX positions and 24 closed out — a net gain of 2 holders — while 19 added to existing stakes and 18 trimmed.

The largest buyer was BlackRock, adding an estimated $14.1M. The largest seller was Foresite Capital Management V, cutting an estimated $6.77M.

  • 73 institutional investors held Compass Therapeutics (CMPX) as of Q2 2023, up from 72 in Q1 2023.
  • Funds reported $288M of Compass Therapeutics stock for Q2 2023, up 7.9% quarter-over-quarter.
  • 26 funds opened new Compass Therapeutics positions in Q2 2023 and 24 closed out, a net change of +2 holders.
  • The largest Compass Therapeutics buyer in Q2 2023 was BlackRock, an estimated $14.1M added.
  • The largest Compass Therapeutics seller in Q2 2023 was Foresite Capital Management V, an estimated $6.77M sold.

Based on aggregated 13F filings for Q2 2023.